Article ID Journal Published Year Pages File Type
5825127 Clinical Therapeutics 2015 21 Pages PDF
Abstract
Sovaldi® represents an enormous advance in the care of some populations of HCV-infected patients, but also a major cost burden to health plans. As the first of a number of anticipated, paradigm-changing drugs to treat medical conditions affecting large patient populations, Sovaldi® should act as a wake-up call for all health care stakeholders to engage in a meaningful, fact-based discussion about managing the cost of innovative new drugs to balance the needs of drug manufacturers, health plans, providers, and, above all, patients.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, ,